just a ramble for mg, page-35

Hi mg,
Your initial excitement was probably more justified than the following market induced disappointment.

If P&G would not have had a 2 year relationship with OBJ already, negotiated for nearly 7 months the terms of this particular agreement on the heels of successful testing, I might agree with you here.
In this scenario though, the events leading to this announcements allowed for an exclusive development agreement.

Even the most critical observer would have to get suspicious after the second global enters an exclusive agreement. The only reason why market ignores us is due to the fact that no milestone payments are mentioned.

This though can eventuate from either GSK's or P&G's side at any time from now on since exclusivity is agreed upon.
Market tends to react late in the game, usually pays to be in early before that happens.



As for short term trades.
ANP was a good trade, but I warned on the thread to not get carried away and avoid buying above 2 cents as the recent run was option conversion related.
ANP now becomes very attractive again in price and is a good bottom pick at 1.6/ 1.5 cents.
Same goes for ESI, it has bottomed out and with finances guaranteed to arrive soon an appreciation in price is highly likely within the arrival of the carbon tax.

Please do you own research regarding those stocks.
The above mentioned is my personal opinion only.